The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SKYE | -67.46% | -85.37% | -31.89% | -100% |
| S&P | +12.83% | +86.37% | +13.24% | +229% |
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. It focuses on the treatment of a spectrum of diseases, as well as utilizing bioengineering in drug design. Its product pipeline includes SBI-100 and SBI-200. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$178.90K | -171.1% |
| Market Cap | $121.78M | 2.7% |
| Market Cap / Employee | $7.61M | 0.0% |
| Employees | 16 | 45.5% |
| Net Income | -$12,754.66K | -227.2% |
| EBITDA | -$13,085.63K | -38.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $18.44M | -75.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $120.21K | 11.2% |
| Short Term Debt | $201.64K | 143.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -83.39% | -39.7% |
| Return On Invested Capital | 407.47% | -30.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13,364.38K | -97.1% |
| Operating Free Cash Flow | -$13,364.38K | -153.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.13 | 0.72 | 2.19 | 2.79 | 84.99% |
| Price to Tangible Book Value | 1.13 | 0.72 | 2.19 | 2.79 | 84.99% |
| Enterprise Value to EBITDA | -3.71 | -0.37 | -6.51 | -9.24 | 15.74% |
| Return on Equity | -80.5% | -47.3% | -72.8% | -94.3% | 72.05% |
| Total Debt | $455.59K | $412.11K | $367.54K | $321.85K | 68.51% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
